3-amino-3-(3,5-dichloro-phenyl)-propionic acid ethyl ester | 147524-80-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-amino-3-(3,5-dichloro-phenyl)-propionic acid ethyl ester
• 英文别名: ethyl 3-amino-3-[3,5-dichlorophenyl]propanoate hydrochloride；ethyl 3-amino-3-(3,5-dichlorophenyl)propanoate；ethyl-DL-3-amino-3-(3,5-dichlorophenyl)propionate；ethyl DL-3-amino-3-(3,5-dichlorophenyl)propionate
• CAS: 147524-80-9
• 化学式: C₁₁H₁₃Cl₂NO₂
• 分子量: 262.136
• InChiKey: VEXKYYBQZJWWSL-UHFFFAOYSA-N

物化性质

• 沸点：
  350.6±42.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-amino-3-(3,5-dichloro-phenyl)-propionic acid ethyl ester 在 盐酸 、 potassium dihydrogenphosphate 、 水 、 sodium hydroxide 作用下， 反应 49.0h， 生成 ethyl (3S)-3-amino-3-[3,5-dichlorophenyl]propanoate hydrochloride
  参考文献：
  名称：

  [EN] META-AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS PAN INTEGRIN ANTAGONISTS
  [FR] DÉRIVÉS D'ACIDE AMINOBENZOÏQUE MÉTA-AZACYCLIQUE À TITRE D'ANTAGONISTES DE PAN-INTÉGRINE

  摘要：

  本公开提供了以下公式的药物代理：其中变量在此处定义。还提供了包含这种药物代理的药物组合物、工具包和制造品。还提供了使用这种药物代理治疗各种疾病和疾病的方法。

  公开号：

  WO2017117538A1
• 作为产物：
  描述：

  3,5-二氯苯甲醛 在 乙酸铵 、 盐酸 作用下， 以 异丙醇 为溶剂， 生成 3-amino-3-(3,5-dichloro-phenyl)-propionic acid ethyl ester
  参考文献：
  名称：

  R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors

  摘要：

  The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.034

文献信息

• Peptide mimetic compounds useful as platelet aggregation inhibitors
  申请人：G. D. Searle & Co.

  公开号：US05220050A1

  公开（公告）日：1993-06-15

  This invention relates to having the following formula ##STR1## or a pharmaceutically acceptable salt which are useful in the inhibition of platelet aggregation. This invention also relates to pharmaceutical compositions of such phenyl amidines derivatives.

  这项发明涉及具有以下公式##STR1##或其药用可接受盐，用于抑制血小板聚集。该发明还涉及这类苯基脲衍生物的药物组合物。
• [EN] AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] AMIDES D'AZOLE ET AMINES EN TANT QU'INHIBITEURS D'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089358A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了Formula (I)的化合物：(Formula (I))，或其立体异构体、互变异构体、或其药学上可接受的盐或溶剂化合物，其中所有变量如本文所定义。这些化合物是αv-含有整合素的抑制剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或症状，如病理纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病的方法。
• [EN] META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS<br/>[FR] DERIVES DE LA META-GUANIDINE, DE L'UREE, DE LA THIO-UREE OU DE L'ACIDE AMINOBENZOIQUE AZACYCLIQUE UTILISES COMME ANTAGONISTES DE L'INTEGRINE
  申请人：G.D. SEARLE & CO.

  公开号：WO1997008145A1

  公开（公告）日：1997-03-06

  (EN) The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein A is (a) or (b) or (c) or (d) pharmaceutical compositions thereof and methods of using such compounds and compositions as $g(a)v$g(b)3 integrin antagonists.(FR) L'invention concerne une classe de composés représentés par la formule I et leurs sels acceptables sur le plan pharmaceutique. Dans cette formule, A est (a) ou (b) ou (c) ou (d). L'invention concerne également des préparations pharmaceutiques contenant ces composés, ainsi que des procédés d'utilisation de ces composés et de ces préparations comme antagonistes de l'intégrine $g(a)v$g(b)3.

  本发明涉及一类由公式（I）或其药学上可接受的盐所表示的化合物，其中A是（a）或（b）或（c）或（d），以及这些化合物和组合物作为$g(a)v$g(b)3整合素拮抗剂的药物组合物和使用方法。本发明还涉及包含这些化合物的药物制剂以及将这些化合物和制剂作为$g(a)v$g(b)3整合素拮抗剂的使用方法。
• Inhibitors of integrin avb6
  申请人：Staehle Wolfgang

  公开号：US20050153902A1

  公开（公告）日：2005-07-14

  Novel biphenyl derivatives of the general formula I in which R 1 , R 1′, R 1″ , R 2 , R 2′ , R3 and n are as defined in Patent claim 1 , stereoisomers thereof and physiologically acceptable salts or solvates thereof are novel integrin inhibitors which preferentially inhibit the αvβ6 integrin receptor. The novel compounds can be used, in particular, as medicaments.

  通用公式I的新型二苯基衍生物，其中R1、R1'、R1"、R2、R2'、R3和n如专利权要求1中所定义，其立体异构体和生理上可接受的盐或溶剂化物是新型整合素抑制剂，其优选抑制αvβ6整合素受体。这些新型化合物可以特别用作药物。
• Inhibitors of integrin αvβ6
  申请人：Merck Patent GmbH

  公开号：US07138417B2

  公开（公告）日：2006-11-21

  Novel biphenyl derivatives of the general formula I in which R1, R1′, R1″, R2, R2′, R3 and n are as defined in Patent claim 1, stereoisomers thereof and physiologically acceptable salts or solvates thereof are novel integrin inhibitors which preferentially inhibit the αvβ6 integrin receptor. The novel compounds can be used, in particular, as medicaments

  具有一般式I的新型联苯衍生物，其中R1，R1'，R1''，R2，R2'，R3和n如专利要求1中所定义，其立体异构体和生理上可接受的盐或溶剂化物是新型整合素抑制剂，其优先抑制αvβ6整合素受体。这些新型化合物可以特别用作药物。